Clinical efficacy and prognosis of adjuvant radiotherapy for adenoid cystic carcinoma of head and neck salivary gland
Wang Xin1, Dou Shengjin2, Li Rongrong2, Zhang Lin2, Chen Gang1, Zhu Guopei2
1Department of Radiation Oncology, Huangpu Branch, Shanghai Ninth People′s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China; 2Department of Oral and Maxillofacial-Head Neck Oncology, Shanghai Ninth People′s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China
Abstract：Objective To investigate the optimal treatment modalities and prognostic factors of adenoid cystic carcinoma of the head and neck salivary gland. Methods From January 2016 to December 2018, clinical data of 166 patients with adenoid cystic carcinoma of the head and neck salivary gland who received postoperative radiotherapy at Department of Radiation Oncology of the Ninth People′s Hospital of Shanghai Jiao Tong University School of Medicine were retrospectively analyzed. The survival analysis was performed by Kaplan-Meier method. Univariate prognostic analysis was conducted by log-rank test. Multivariate prognostic analysis was carried out by Cox proportional hazard regression model. Results Among 166 enrolled patients, 70 cases were male and 96 female with an average age of 53 years (18 to 71 years). The median follow-up time was 31.2 months (8.6-63.1 months). Sixty-six patients underwent radical surgery (extended resection across the anatomical areas outside the tumor bed, pursuing negative margins of various resections), and the remaining 100 patients underwent conservative surgery (only extended resection of lesions, not pursuing negative nerve resection margins). The median dose of postoperative radiotherapy was 66Gy (54-70Gy). Seventy-three patients were treated with TP regime due to positive or close margins and 9 cases of cervical lymph node metastasis. The 3-and 5-year overall survival (OS), locoregional recurrence-free survival (LRRFS), distant metastasis-free survival (DMFS), progression-free survival (PFS) rates were 95% and 95%, 93% and 93%, 74% and 66%, 73% and 65%, respectively. Seven patients experienced primary lesion recurrence, 5 cases of regional lymph node recurrence and 38 cases of distant metastasis. T3-T4 stage,lymph nodes (+),stage IV, solid pathologic subtype, Ki-67≥10% and perineural invasion were associated with worse PFS and DMFS. Multivariate analysis demonstrated that only solid pathologic subtype was the independent prognostic factor of OS, LRRFS, PFS and DMFS. Conclusions The local control rate of salivary gland adenoid cystic carcinoma can be improved by postoperative intensity-modulated radiotherapy (IMRT) with a recommended dose of ≥66Gy. Solid pathologic subtype is the most important adverse prognostic factor.
Wang Xin,Dou Shengjin,Li Rongrong et al. Clinical efficacy and prognosis of adjuvant radiotherapy for adenoid cystic carcinoma of head and neck salivary gland[J]. Chinese Journal of Radiation Oncology, 2021, 30(8): 770-774.
[1] Coca-Pelaz A, Rodrigo JP, Bradley PJ, et al. Adenoid cystic carcinoma of the head and neck—An update[J]. Oral Oncol, 2015, 51(7):652-661. DOI:10.1016/j.oraloncology.2015.04.005. [2] Subramaniam T, Lennon P, O′Neill JP. Ongoing challenges in the treatment of adenoid cystic carcinoma of the head and neck[J]. Ir J Med Sci, 2015, 184(3):583-590. DOI:10.1007/s11845-015-1298-1. [3] Westra WH. The surgical pathology of salivary gland neoplasms[J]. Otolaryngol Clin North Am, 1999, 32(5):919-943. DOI:10.1016/s0030-6665(05)70182-1. [4] Iseli TA, Karnell LH, Graham SM, et al. Role of radiotherapy in adenoid cystic carcinoma of the head and neck[J]. J Laryngol Otol, 2009, 123(10):1137-1144. DOI:10.1017/S0022215109990338. [5] Dillon PM, Chakraborty S, Moskaluk CA, et al. Adenoid cystic carcinoma:a review of recent advances, molecular targets, and clinical trials[J]. Head Neck, 2016, 38(4):620-627. DOI:10.1002/hed.23925. [6] Kokemueller H, Eckardt A, Brachvogel P, et al. Adenoid cystic carcinoma of the head and neck—a 20 years experience[J]. Int J Oral Maxillofac Surg, 2004, 33(1):25-31. DOI:10.1054/ijom.2003.0448. [7] Garden AS, Weber RS, Morrison WH, et al. The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation[J]. Int J Radiat Oncol Biol Phys, 1995, 32:619–626. DOI:10.1016/0360-3016(95)00122-F. [8] Spiro RH. Management of malignant tumors of the salivary glands[J]. Oncology (Williston Park), 1998, 12(5):671-680;discussion 683. [9] Jeong IS, Roh JL, Cho KJ, et al. Risk factors for survival and distant metastasis in 125 patients with head and neck adenoid cystic carcinoma undergoing primary surgery[J]. J Cancer Res Clin Oncol, 2020, 146(5):1343-1350. DOI:10.1007/s00432-020-03170-5. [10] Atallah S, Casiraghi O, Fakhry N, et al. A prospective multicentre REFCOR study of 470 cases of head and neck Adenoid cystic carcinoma:epidemiology and prognostic factors[J]. Eur J Cancer, 2020, 130:241-249. DOI:10.1016/j.ejca.2020.01.023. [11] Kumar PP, Patil AA, Ogren FP, et al. Intracranial skip metastasis from parotid and facial skin tumors:mechanism, diagnosis, and treatment[J]. J Natl Med Assoc, 1993, 85(5):369-374. DOI:10.1016/0885-3924(93)90134-H. [12] Shen C, Xu T, Huang C, et al. Treatment outcomes and prognostic features in adenoid cystic carcinoma originated from the head and neck[J]. Oral Oncol, 2012, 48(5):445-449. DOI:10.1016/j.oraloncology.2011.12.002. [13] Miglianico L, Eschwege F, Marandas P, et al. Cervico-facial adenoid cystic carcinoma:study of 102 cases. Influence of radiation therapy[J]. Int J Radiat Oncol Biol Phys, 1987, 13(5):673-678. DOI:10.1016/0360-3016(87)90284-7. [14] Gomez DR, Hoppe BS, Wolden SL, et al. Outcomes and prognostic variables in adenoid cystic carcinoma of the head and neck:a recent experience[J]. Int J Radiat Oncol Biol Phys, 2008, 70(5):1365-1372. DOI:10.1016/j.ijrobp.2007.08.008. [15] Chen AM, Bucci MK, Weinberg V, et al. Adenoid cystic carcinoma of the head and neck treated by surgery with or without postoperative radiation therapy:prognostic features of recurrence[J]. Int J Radiat Oncol Biol Phys, 2006, 66(1):152-159. DOI:10.1016/j.ijrobp.2006.04.014. [16] Ali S, Palmer FL, Katabi N, et al. Long-term local control rates of patients with adenoid cystic carcinoma of the head and neck managed by surgery and postoperative radiation[J]. Laryngoscope, 2017, 127(10):2265-2269. DOI:10.1002/lary.26565. [17] Balamucki CJ, Amdur RJ, Werning JW, et al. Adenoid cystic carcinoma of the head and neck[J]. Am J Otolaryngol, 2012, 33(5):510-518. DOI:10.1016/j.amjoto.2011.11.006. [18] Dubergé T, Bénézery K, Resbeut M, et al. Adenoid cystic carcinoma of the head and neck:a retrospective series of 169 cases[J]. Cancer Radiother, 2012, 16(4):247-256. DOI:10.1016/j.canrad.2012.02.003. [19] Lloyd S, Yu JB, Wilson LD, et al. Determinants and patterns of survival in adenoid cystic carcinoma of the head and neck, including an analysis of adjuvant radiation therapy[J]. Am J Clin Oncol, 2011, 34(1):76-81. DOI:10.1097/COC.0b013e3181d26d45. [20] Ellington CL, Goodman M, Kono SA, et al. Adenoid cystic carcinoma of the head and neck:incidence and survival trends based on 1973-2007 surveillance, Epidemiology, and End Results data[J]. Cancer, 2012, 118(18):4444-4451. DOI:10.1002/cncr.27408. [21] Amit M, Binenbaum Y, Sharma K, et al. Analysis of failure in patients with adenoid cystic carcinoma of the head and neck. An international collaborative study[J]. Head Neck, 2014, 36(7):998-1004. DOI:10.1002/hed.23405. [22] Min R, Siyi L, Wenjun Y, et al. Salivary gland adenoid cystic carcinoma with cervical lymph node metastasis:a preliminary study of 62 cases[J]. Int J Oral Maxillofac Surg, 2012, 41(8):952-957. DOI:10.1016/j.ijom.2012.04.023. [23] Chen AM, Garcia J, Lee NY, et al. Patterns of nodal relapse after surgery and postoperative radiation therapy for carcinomas of the major and minor salivary glands:what is the role of elective neck irradiation?[J]. Int J Radiat Oncol Biol Phys, 2007, 67(4):988-994. DOI:10.1016/j.ijrobp.2006.10.044. [24] Hutcheson JA, Vural E, Korourian S, et al. Neural cell adhesion molecule expression in adenoid cystic carcinoma of the head and neck[J]. Laryngoscope, 2000, 110(6):946-948. DOI:10.1097/00005537-200006000-00011. [25] Rhee CS, Won TB, Lee CH, et al. Adenoid cystic carcinoma of the sinonasal tract:treatment results[J]. Laryngoscope, 2006, 116(6):982-986. DOI:10.1097/01.mlg.0000216900.03188.48. [26] Liebig C, Ayala G, Wilks JA, et al. Perineural invasion in cancer:a review of the literature[J]. Cancer, 2009, 115(15):3379-3391. DOI:10.1002/cncr.24396.
2021, Vol. 30 
